Moneycontrol PRO

Buy Torrent Pharmaceuticals; target of Rs 3250: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3250 in its research report dated May 26, 2022.

May 30, 2022 / 06:24 PM IST
  • bselive
  • nselive
Todays L/H

Prabhudas Lilladher's research report on Torrent Pharmaceuticals

Torrent Pharma’s (TRP) H2FY22 performance was muted however we believe profitability/margins to normalize from FY23, aided by price hike in branded generic business and cost optimization steps. TRP’s high exposure to branded generic business (~70% of total revenues) and chronic therapies provides comfort. Going ahead, timely resolution of plants will pick-up revenue growth in US and benefit operating leverage. We expect 20% EPS CAGR over FY22-24E.


We have cut our FY23 and FY24E EPS by ~10%. Maintain ‘Buy’ rating with revised TP of Rs3,250/share, 30x FY24E EPS.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 30, 2022 06:24 pm
ISO 27001 - BSI Assurance Mark